2-(苄基氨基)丙酸乙酯 | 64892-53-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(苄基氨基)丙酸乙酯
• 英文名称: N-benzylalanine ethyl ester
• 英文别名: ethyl 2-(benzylamino)propanoate；2-benzylaminopropionic acid ethyl ester
• CAS: 64892-53-1
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.272
• InChiKey: QDBFFNIUCGDMQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(苄基氨基)丙酸乙酯 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 2-N-苄基氨基丙酸
  参考文献：
  名称：

  Design of Selective Peptidomimetic Agonists for the Human Orphan Receptor BRS-3

  摘要：

  New tool substances may help to unravel the physiological role of the human orphan receptor BRS-3 and its possible use as a drug target for the treatment of obesity and cancer. In continuation of our work on BRS-3, the solid- and solution-phase synthesis of a library of low molecular weight peptidomimetic agonists based on the recently developed short peptide agonist 4 is described. Functional potencies of the compounds were determined measuring calcium mobilization in a fluorometric imaging plate reader (FLIPR) assay. Focusing on the N-terminus, the D-Phe-Gln moiety of 4 was modified in a combinatorial. SAR-oriented medicinal chemistry approach. With the incorporation of N-arylated glycine and alanine building blocks azaglycine, piperazine, or piperidine and the synthesis of semicarbazides and semicarbazones, a number of highly potent and selective compounds with a reduced number of peptide bonds were obtained, which also should have enhanced metabolic stability.

  DOI：

  10.1021/jm0210921
• 作为产物：
  描述：

  丙氨酸乙酯 在 镍 氢气 作用下， 以 乙醇 为溶剂， 生成 2-(苄基氨基)丙酸乙酯
  参考文献：
  名称：

  Szarvasi,E. et al., European Journal of Medicinal Chemistry, 1976, vol. 11, p. 115 - 124

  摘要：

  DOI：

文献信息

• [EN] MYOGLOBIN-BASED CATALYSTS FOR CARBENE TRANSFER REACTIONS<br/>[FR] CATALYSEURS À BASE DE MYOGLOBINE POUR RÉACTIONS DE TRANSFERT DE CARBÈNE
  申请人：UNIV ROCHESTER

  公开号：WO2016086015A1

  公开（公告）日：2016-06-02

  Methods are provided for carrying out carbene transfer transformations such as olefin cyclopropanation reactions, carbene heteroatom-H insertion reactions (heteroatom = N, S, Si), sigmatropic rearrangement reactions, and aldehyde olefination reactions with high efficiency and selectivity by using a novel class of myoglobin-based biocatalysts. These methods are useful for the synthesis of a variety of organic compounds which contain one or more new carbon-carbon or carbon-heteroatom (N, S, or Si) bond. The methods can be applied for conducting these transformations in vitro (i.e., using the biocatalyst in isolated form) and in vivo (i.e., using the biocatalyst in a whole cell system).

  提供了一种方法来进行碳烯转移反应，如烯烃环丙烷化反应，碳烯杂原子-H插入反应（杂原子= N，S，Si），σ迁移重排反应和醛烯化反应，通过使用一种新型的基于肌红蛋白的生物催化剂，可以高效和选择性地进行。这些方法对于合成含有一个或多个新碳-碳或碳-杂原子（N，S或Si）键的各种有机化合物非常有用。这些方法可以应用于体外（即使用分离形式的生物催化剂）和体内（即在整个细胞系统中使用生物催化剂）进行这些转化。
• [EN] KRAS G12C INHIBITORS<br/>[FR] INHIBITEURS DE KRAS G12C
  申请人：MIRATI THERAPEUTICS INC

  公开号：WO2017201161A1

  公开（公告）日：2017-11-23

  The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

  本发明涉及抑制KRas G12C的化合物。特别是，本发明涉及不可逆地抑制KRas G12C活性的化合物，包括含有这些化合物的药物组合物及其使用方法。
• KRAS G12C INHIBITORS
  申请人：Mirati Therapeutics, Inc.

  公开号：US20190144444A1

  公开（公告）日：2019-05-16

  The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

  本发明涉及抑制KRas G12C的化合物。特别地，本发明涉及不可逆抑制KRas G12C活性的化合物、包含这些化合物的药物组合物及其使用方法。
• Direct and indirect reductive amination of aldehydes and ketones with solid acid-activated sodium borohydride under solvent-free conditions
  作者：Byung Tae Cho、Sang Kyu Kang

  DOI：10.1016/j.tet.2005.04.039

  日期：2005.6

  A simple and convenient procedure for reductive amination of aldehydes and ketones using sodium borohydride activated by boric acid, p-toluenesulfonic acid monohydrate or benzoic acid as reducing agent under solvent-free conditions is described.

  描述了一种简单方便的程序，用于在无溶剂条件下，使用硼酸，对甲苯磺酸一水合物或苯甲酸作为还原剂活化的硼氢化钠还原性胺化醛和酮。
• [EN] AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS D'AZÉTIDINE UTILES POUR LE TRAITEMENT DE MALADIES MÉTABOLIQUES ET INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2012098033A1

  公开（公告）日：2012-07-26

  Compounds are disclosed that have a formula represented by the following: These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.

  披露了具有以下表示的公式的化合物：这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如炎症性疾病、传染病、自身免疫疾病、涉及免疫细胞功能受损的疾病、心脏代谢疾病和/或增殖性疾病，举例不限。